Bitter sweet: Fournier’s Gangrene and SGLT2 inhibitors
Diabetes mellitus, especially type 2 is becoming the biggest epidemic of the 21st century affecting more than 415 million adults globally and expected to increase to more than 640 million adults by 2040. Patients with diabetes are at high risk for adverse outcomes, notably cardiovascular disease wit...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
University of Ottawa
2019-12-01
|
| Series: | University of Ottawa Journal of Medicine |
| Subjects: | |
| Online Access: | https://uottawa.scholarsportal.info/ottawa/index.php/uojm-jmuo/article/view/4476 |
| _version_ | 1811315209852157952 |
|---|---|
| author | Coralea Kappel |
| author_facet | Coralea Kappel |
| author_sort | Coralea Kappel |
| collection | DOAJ |
| description | Diabetes mellitus, especially type 2 is becoming the biggest epidemic of the 21st century affecting more than 415 million adults globally and expected to increase to more than 640 million adults by 2040. Patients with diabetes are at high risk for adverse outcomes, notably cardiovascular disease with an increased risk of death. In fact, the 2018 Canadian Diabetes Association (CDA) guidelines have updated the type 2 diabetes management algorithm; if the patient has clinical cardiovascular disease, an antihyperglycemic agent with demonstrated cardiovascular (CV) benefit should be added. There is a growing armamentarium of therapies with Health Canada-approved CV benefit include two from the sodium-glucose co-transporter 2 (SGLT2) inhibitors class namely Canagliflozin and empagliflozin. Despite their many advantages, the Food and Drug Administration (FDA) issued a black box warning for associated necrotizing fasciitis of the perineum in diabetes treated with SGLT2 inhibitors. This case report highlights a case of Fournier’s gangrene (FG) in a male treated with empagliflozin for type 2 diabetes. |
| first_indexed | 2024-04-13T11:26:15Z |
| format | Article |
| id | doaj.art-5335939814af4f3f95ae3280b710be0a |
| institution | Directory Open Access Journal |
| issn | 2292-650X 2292-6518 |
| language | English |
| last_indexed | 2024-04-13T11:26:15Z |
| publishDate | 2019-12-01 |
| publisher | University of Ottawa |
| record_format | Article |
| series | University of Ottawa Journal of Medicine |
| spelling | doaj.art-5335939814af4f3f95ae3280b710be0a2022-12-22T02:48:41ZengUniversity of OttawaUniversity of Ottawa Journal of Medicine2292-650X2292-65182019-12-019210.18192/uojm.v9i2.4476Bitter sweet: Fournier’s Gangrene and SGLT2 inhibitorsCoralea Kappel0University of OttawaDiabetes mellitus, especially type 2 is becoming the biggest epidemic of the 21st century affecting more than 415 million adults globally and expected to increase to more than 640 million adults by 2040. Patients with diabetes are at high risk for adverse outcomes, notably cardiovascular disease with an increased risk of death. In fact, the 2018 Canadian Diabetes Association (CDA) guidelines have updated the type 2 diabetes management algorithm; if the patient has clinical cardiovascular disease, an antihyperglycemic agent with demonstrated cardiovascular (CV) benefit should be added. There is a growing armamentarium of therapies with Health Canada-approved CV benefit include two from the sodium-glucose co-transporter 2 (SGLT2) inhibitors class namely Canagliflozin and empagliflozin. Despite their many advantages, the Food and Drug Administration (FDA) issued a black box warning for associated necrotizing fasciitis of the perineum in diabetes treated with SGLT2 inhibitors. This case report highlights a case of Fournier’s gangrene (FG) in a male treated with empagliflozin for type 2 diabetes.https://uottawa.scholarsportal.info/ottawa/index.php/uojm-jmuo/article/view/4476sglt2 inhibitorsfournier's gangrenepharmacotherapymedication adverse effectsurology |
| spellingShingle | Coralea Kappel Bitter sweet: Fournier’s Gangrene and SGLT2 inhibitors University of Ottawa Journal of Medicine sglt2 inhibitors fournier's gangrene pharmacotherapy medication adverse effects urology |
| title | Bitter sweet: Fournier’s Gangrene and SGLT2 inhibitors |
| title_full | Bitter sweet: Fournier’s Gangrene and SGLT2 inhibitors |
| title_fullStr | Bitter sweet: Fournier’s Gangrene and SGLT2 inhibitors |
| title_full_unstemmed | Bitter sweet: Fournier’s Gangrene and SGLT2 inhibitors |
| title_short | Bitter sweet: Fournier’s Gangrene and SGLT2 inhibitors |
| title_sort | bitter sweet fournier s gangrene and sglt2 inhibitors |
| topic | sglt2 inhibitors fournier's gangrene pharmacotherapy medication adverse effects urology |
| url | https://uottawa.scholarsportal.info/ottawa/index.php/uojm-jmuo/article/view/4476 |
| work_keys_str_mv | AT coraleakappel bittersweetfourniersgangreneandsglt2inhibitors |